Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

PURPOSE: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90. This study was carried out in Japanese patients to determine the maximum tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922. METHODS: Japanese patients with advanc...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Doi, Toshihiko, Onozawa, Yusuke, Fuse, Nozomu, Yoshino, Takayuki, Yamazaki, Kentaro, Watanabe, Junichiro, Akimov, Mikhail, Robson, Matthew, Boku, Narikazu, Ohtsu, Atsushi
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2014
Предметы:
Clinical Trial Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143601/
https://ncbi.nlm.nih.gov/pubmed/25059319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2521-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы